-
Mashup Score: 0HOME - 18th Annual New York Lung Cancers Symposium® - 8 month(s) ago
OverviewAt the New York Lung Cancers Symposium® attendees will experience a comprehensive overview of lung cancer diagnoses and multidisciplinary treatment. Now in its 18th year, the agenda for this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play to ensure the most accurate diagnosis of lung…
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - 24th Annual International Lung Cancer Congress® - 8 month(s) ago
24th Annual International Lung Cancer Congress®.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ESMO Preceptorship on NSCLC 2023: Singapore - 1 year(s) ago
10-11 January 2023, Singapore
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4ESMO Virtual Advanced Course on KRAS targeting in NSCLC 2022 - 2 year(s) ago
Virtual, 28-29 November 2022
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ESMO Virtual Advanced Course on #KRAS Targeting in #NSCLC: Function and biology; spectrum, platforms & strategies for molecular testing; emerging therapeutic strategies & clinical research; & more. ⏰ 28 - 29 Nov 🔗 https://t.co/87IJGZ6Log #lscm @LauraMezquitaMD @danieltanmd https://t.co/UQWOohD2Pk
-
-
Mashup Score: 0Abivertinib Demonstrates Response and Survival Benefits in Pretreated EGFR T790M–Mutant NSCLC - 2 year(s) ago
The novel third-generation EGFR inhibitor abivertinib generated a positive overall response rate and overall survival in heavily pretreated Chinese patients with EGFR T790M–mutated non–small cell lung cancer who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial (NCT02330367).
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Abivertinib Demonstrates Response and Survival Benefits in Pretreated EGFR T790M–Mutant NSCLC - 2 year(s) ago
The novel third-generation EGFR inhibitor abivertinib generated a positive overall response rate and overall survival in heavily pretreated Chinese patients with EGFR T790M–mutated non–small cell lung cancer who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial (NCT02330367).
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 17
IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with…
Source: The LancetCategories: Latest Headlines, Oncologists1Tweet-
Fresh out of #ESMO21 & published in @TheLancet 📰 IMpower0️⃣1️⃣0️⃣ ☑️ DFS benefit w/atezolizumab 🆚 BSC after adj chemo🧪in resected stage II–IIIA #NSCLC ☑️Benefit in subgroup w:PDL1 expression ✅A promising tx in resected early-stage NSCLC @OncoAlert 🚨 https://t.co/5fgOKinms8 https://t.co/epCWqrVM70
-
-
Mashup Score: 16FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion - 4 year(s) ago
FDA approves Retevmo (selpercatinib) for patients with lung and thyroid cancers and an RET gene alteration.
Categories: Hem/Oncs, Latest HeadlinesTweet
Get ready to learn the latest data on immunotherapy and targeted agents in metastatic lung cancers and much more from #lungcancer experts at this year’s New York Lung Symposium! Register: https://t.co/p9a5gZ3kk7 #lscm #NYL23 #gotoPER @DrSteveMartin @MSKCancerCenter https://t.co/UnyKuznIY0